Heloisa Porath

Heloisa Porath

Auto-generated profile, based on publicly available information

Heloisa Porath

Faculdade Evangélica Mackenzie do Paraná, Curitiba, PR, Brasil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in BioSCIENCE
Verified
Journal Article
Open access
PDF file
PJPaulo Eduardo Dietrich Jaworski
Paulo Eduardo Dietrich Jaworski
AMAdemir José de Moura-Junior
Ademir José de Moura-Junior
VBVinicius Dalledone Bittar
Vinicius Dalledone Bittar
HPHeloisa Porath
Heloisa Porath
FOFlávia Vargas de Oliveira
Flávia Vargas de Oliveira
GSGuilherme Vieira Cavalcante da Silva
Guilherme Vieira Cavalcante da Silva

24 June 2022 in REVISTA MÉDICA DO PARANÁ
Verified
Journal Article
Open access
PDF file
AGAndressa Dalle Corte Galvan
Andressa Dalle Corte Galvan
HPHeloísa Porath
Heloísa Porath
JSJoão Carlos Simõe
João Carlos Simõe
- Introduction: To treat breast cancer, one of the medications used is trastuzumab, a monoclonal antibody that blocks the HER-2 oncogene and can lead to type II heart failure. Objective: To study the profile of patients affected by cardiotoxicity during treatment with trastuzumab, identifying their risk factors. Methods: Transversal observational retrospective study, with analysis of the patient’s medical record that finished the treatment using trastuzumab. Results: Of the analyzed patients, 40% developed heart failure, with a medium age of 57,3 years old, and the most important risk factors related to it were: smoking, neoadjuvant treatment with trastuzumab, tumors bigger than 5 cm and positive lymph nodes. The decrease of the left ventricular ejection fraction was more intense in the first six months of treatment, with only partial recovery after one year using the monoclonal antibody. Conclusion: Risk factors for cardiotoxicity during treatment with trastuzumab were smoking, tumor larger than 5 cm, lymph node metastasis and neoadjuvant treatment. RESUMO - Racional: Para o tratamento do câncer de mama, um dos medicamentos utilizados é o trastuzumabe, anticorpo monoclonal que bloqueia o oncogene HER-2, e que pode levar a insuficiência cardíaca tipo II. Objetivo: Estudar o perfil dos pacientes acometidos pela cardiotoxicidade durante o tratamento com trastuzumabe, identificando seus fatores de risco. Métodos: Estudo transversal observacional retrospectivo com análise de prontuários de pacientes que realizaram tratamento com trastuzumabe. Resultados: Das pacientes analisadas, 40,0% desenvolveram insuficiência cardíaca, com média de idade de 57,3 anos. Destas, os fatores de risco foram: tabagismo, uso do trastuzumabe neoadjuvante, tumores maiores que 5 cm e com linfonodos positivos. A redução da fração de ejeção ventricular esquerda foi mais importante nos primeiros seis meses de tratamento e com recuperação apenas parcial ao final de um ano do uso do anticorpo monoclonal. Conclusão: A cardiotoxicidade durante o tratamento com trastuzumabe teve como fatores de risco o tabagismo, tumor maior que 5 cm, metástase linfonodal e tratamento neoadjuvante.

27 October 2022 in BioSCIENCE
Verified
Journal Article
Open access
PDF file
PJPaulo Eduardo Dietrich Jaworski
Paulo Eduardo Dietrich Jaworski
RBRafael Rodrigues Spinola Barbosa
Rafael Rodrigues Spinola Barbosa
HPHeloisa Porath
Heloisa Porath
EBEduardo Zanetti Bergamaschi
Eduardo Zanetti Bergamaschi
ALAndrey Francisco Levatti
Andrey Francisco Levatti
Neoplasia de uretra. Exenteração pélvica anterior. Uretra.

27 October 2022 in BioSCIENCE
Verified
Journal Article
Open access
PDF file
PJPaulo Eduardo Dietrich Jaworsk
Paulo Eduardo Dietrich Jaworsk
CKCássio Lamblet Katzer
Cássio Lamblet Katzer
HPHeloisa Porath
Heloisa Porath
DBDirceu Augusto Rudiger Bombardelli
Dirceu Augusto Rudiger Bombardelli
JSJulia Andressa Serpa
Julia Andressa Serpa
GSGuilherme Vieira Cavalcante da Silva
Guilherme Vieira Cavalcante da Silva

27 October 2022 in BioSCIENCE
Verified
Journal Article
Open access
PDF file
PJPaulo Eduardo Dietrich Jaworski
Paulo Eduardo Dietrich Jaworski
RBRafael Rodrigues Spinola Barbosa
Rafael Rodrigues Spinola Barbosa
HPHeloisa Porath
Heloisa Porath
LKLuiz Felipe Ribeiro Kobarg
Luiz Felipe Ribeiro Kobarg
MAMatheus Burkot Alves de Araújo
Matheus Burkot Alves de Araújo

8 November 2021 in Revista de Medicina
Verified
Journal Article
Open access
PDF file
ÁFÁlisson Carvalho de Freitas
Álisson Carvalho de Freitas
HPHeloisa Porath
Heloisa Porath
JRJoão Lucas Aleixes Sampaio Rocha
João Lucas Aleixes Sampaio Rocha
RGRegina Maria Goolkate
Regina Maria Goolkate
RFRaphaella De Paula Ferreira
Raphaella De Paula Ferreira
PRPhillipe Geraldo Teixeira de Abreu Reis
Phillipe Geraldo Teixeira de Abreu Reis
Introduction: Pancreatic cancer is the fourth leading cause of cancer death in Western countries, with a more prevalent incidence in the elderly (1). It presents itself as a neoplasm with high lethality and low survival, surgical resection being the only treatment with curative potential. However, pancreatoduodenectomy (Kausch-Whipple technique) is one of the most difficult surgeries in the gastrointestinal system, due to the great difficulty in accessing the pancreas and its proximity to various delicate and vital structures, requiring advanced knowledge by the surgeon (6). Objective: Evaluate the profile of patients with pancreatic cancer and factors that contribute to the surgical outcome and survival after curative pancreatoduodenectomy. Method: A descriptive retrospective cross-sectional study was carried out through the analysis of records of pancreatoduodenectomy in the period May 2005 – July 2015 at Hospital Erasto Gaertner (HEG) in Curitiba/PR. Variables were analyzed using Student's t-test, non-parametric Mann-Whitney U test, and chi-squared test with Fisher's correction. Survival and disease-free survival rates were evaluated using the Kaplan-Maier method with the log-rank test and survival predictors identified with Cox regression. The SPSS 23.0 and STATA 15 programs were used, with p value being lower than 0.05 considered statistically significant. Results: 98 pancreatoduodenectomy were evaluated and 46 were in male patients and 30 were in patients aged <60 years. Ca 19-9 levels were elevated in 29% of patients before surgery and elevated in 5% after surgery. Regarding the location of the tumor, 77% were pancreatic, 14% were duodenal papilla and 8% were biliary tract. Regarding tumor histology, 81 were adenocarcinoma, 6 were cholangiocarcinoma and 5 were other diagnoses; 29% were well differentiated, 53% moderately and 17% poorly differentiated. About staging, 21% T1, 23% T2, 36% T3 and 18% T4 were found. Factors such as local tumor extension, location of the lesion and surgery time do not show a significant influence on the surgical outcome of these patients. The main postoperative complications were fistula and evisceration. The mean overall survival after surgery at 5 years was 12.24% and this was seen to be significantly higher in the <60 years group (p < 0.01). Discussion and Conclusion: It was seen that pancreatic tumors present in more advanced stages at diagnosis and are more prevalent in the elderly. These characteristics negatively impact 5-year overall survival rates, as this is higher in patients older than 60 years. Early diagnosis remains a challenge for successful treatment with curative potential, and remains a key point for the survival of these patients, as it allows for better staging and better surgical results.